Pulmonary targeting potential of rosuvastatin loaded nanostructured lipid carrier: Optimization by factorial design

International Journal of Pharmaceutics

Volumn 501, Issue 1-2, 2016, Pages 199-210

  Patil Gadhe, Arpana ^a   Pokharkar, Varsha ^a  

^a BHARATI VIDYAPEETH DEEMED UNIVERSITY   (India)

Author keywords

Dry powder for inhalation; Nanostructured lipid carrier; Pulmonary delivery; Rosuvastatin

Indexed keywords

MANNITOL; ROSUVASTATIN; SOLID LIPID NANOPARTICLE; DRUG CARRIER; LIPID; NANOMATERIAL;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DISPERSION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG RELEASE; DRUG TARGETING; DRY POWDER INHALER; ELIMINATION RATE CONSTANT; FACTORIAL DESIGN; FREEZE DRYING; IN VITRO STUDY; IN VIVO STUDY; MALE; MAXIMUM PLASMA CONCENTRATION; MEAN RESIDENCE TIME; NANOENCAPSULATION; NANOPHARMACEUTICS; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PLEIOTROPY; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; VOLUME OF DISTRIBUTION; ANIMAL; CHEMISTRY; INHALATIONAL DRUG ADMINISTRATION; LUNG; MEDICINAL CHEMISTRY; METABOLISM; WISTAR RAT;

ADMINISTRATION, INHALATION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG CARRIERS; DRUG LIBERATION; FREEZE DRYING; LIPIDS; LUNG; MALE; MANNITOL; NANOSTRUCTURES; PARTICLE SIZE; RATS; RATS, WISTAR; ROSUVASTATIN CALCIUM;

EID: 84958177750     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2016.01.080     Document Type: Article

References (60)

1. M.H. Al-Hallak, M.K. Sarfraz, S. Azarmi, W.H. Roa, W.H. Finlay, and R. Löbenberg Pulmonary delivery of inhalable nanoparticles: dry-powder inhalers Thera. Deliv. 2 2011 1313 1324
2. A.J. Ammit, S.A. Kane, and R.A. Panettieri Activation of K-p21ras and N-p21ras but not H-p21ras, is necessary for mitogen-induced human airway smooth muscle proliferation Am. J. Respir. Cell Mol. Biol. 21 1999 719 727
3. S.R.B. Behara, I. Larson, P. Kippax, D.A.V. Morton, and P. Stewart An approach to characterising the cohesive behaviour of powders using a flow titration aerosolisation based methodology Chem. Eng. Sci. 66 2011 1640 1648
4. C. Bergeron, W. Al-Ramli, and Q. Hamid Remodeling in asthma Proc. Am. Thorac. Soc. 6 2009 301 305
5. F.J. Bhavna Ahmad, G. Mittal, G.K. Jain, G. Malhotra, R.K. Khar, and A. Bhatnagar Nanosalbutamol dry powder inhalation: a new approach for treating broncho-constrictive conditions Eur. J. Pharm. Biopharm. 71 2009 282 291
6. P.R. Byron, and J.S. Patton Drug delivery via the respiratory tract J. Aerosol Med. 7 1994 49 75
7. V. Capra, and G.E. Rovati Rosuvastatin inhibits human airway smooth muscle cells mitogenic response to eicosanoid contractile agents Pul. Pharmacol. Ther. 27 2014 10 16
8. V. Capra, M.D. Thompson, A. Sala, D.E. Cole, G. Folco, and G.E. Rovati Cysteinyl-leukotrienes and their receptors in asthma and other inflammatory diseases: critical update and emerging trends Med. Res. Rev. 27 2007 469 527
9. P. Chattopadhyay, B.Y. Shekunov, D. Yim, D. Cipolla, B. Boyd, and S. Farr Production of solid lipid nanoparticle suspensions using supercritical fluid extraction of emulsions (SFEE) for pulmonary delivery using the AERx system Adv. Drug Deliv. Rev. 59 2007 444 453
10. N.Y. Chew, B.Y. Shekunov, H.H. Tong, A.H. Chow, C. Savage, J. Wu, and H.K. Chan Effect of amino acids on the dispersion of disodium cromoglycate powders J. Pharm. Sci. 94 2005 2289 2300
11. M. Chougule, B. Padhi, and A. Misra Nano-liposomal dry powder inhaler of tacrolimus Preparation, characterization, and pulmonary pharmacokinetics Int. J. Nanomed. 2 2007 675 688
12. P. Costa, and L.J.M. Sousa Modeling and comparison of dissolution profiles Eur. J. Pharm. Sci. 13 2001 123 133
13. N.S. Culhane, S.L. Lettieri, and J.R. Skae Rosuvastatin for the treatment of hypercholesterolemia Pharmacotherapy 25 7 2005 990 1000
14. S.C. Das, S.R. Behara, J.B. Bulitta, D.A. Morton, I. Larson, and P.J. Stewart Powder strength distributions for understanding de-agglomeration of lactose powders Pharm. Res. 29 2012 2926 2935
15. N.M. Davies, and M.R. Feddah A novel method for assessing dissolution of aerosol inhaler products Int. J. Pharm. 255 2003 175 187
16. N. El-Gendy, E.M. Gorman, E.J. Munson, and C. Berkland Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution J. Pharm. Sci. 98 2009 2731 2746
17. J.A. Elias, Z. Jack, G. Zhu, R.J. Chupp, and Homer Airway remodeling in asthma J. Clin. Invest. 104 8 1999 1001 1006
18. F. Grasmeijer, and A.H. de Boer The dispersion behaviour of dry powder inhalation formulations cannot be assessed at a single inhalation flow rate Int. J. Pharm. 465 2014 165 168
19. F. Grasmeijer, P. Hagedoorn, H.W. Frijlink, and A.H. De Boer Drug content effects on the dispersion performance of adhesive mixtures for inhalation PLoS One 8 2013 e71339
20. F. Grasmeijer, A.J. Lexmond, M. van den Noort, P. Hagedoorn, A.J. Hickey, H.W. Frijlink, and A.H. de Boer New mechanisms to explain the effects of added lactose fines on the dispersion performance of adhesive mixtures for inhalation PLoS ONE 9 2014 e87825
21. C.J. Hitzman, W.F. Elmquist, L.W. Wattenberg, and T.S. Wiedmann Development of a respirable, sustained release microcarrier for 5-fluorouracil I: in vitro assessment of liposomes, microspheres and lipid coated nanoparticles J. Pharm. Sci. 95 2006 1114 1126 (last date accessed July 2015) http://www.researchreview.com.au/Approved-Crestor-PI.pdf
22. J.N. Israelachvili Intermolecular and Surface Forces 3rd ed. 2011 Academic Press USA
23. P.A. Jaques, and C.S. Kim Measurement of total lung deposition of inhaled ultrafine particles in healthy men and women Inhal. Toxiccol. 12 2000 715 731
24. V. Jenning, A.F. Thunemann, and S.H. Gohla Characterization of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids Int. J. Pharm. 199 2000 167 177
25. P.R. Johnson, M. Roth, M. Tamm, M. Hughes, Q. Ge, G. King, J.K. Burgess, and J.L. Black Airway smooth muscle cell proliferation is increased in asthma Am. J. Respir. Crit. Care Med. 164 2001 474 477
26. M. Joshi, and A. Misra Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung Clin. Exp. Pharmacol. Physiol. 30 2003 153 156
27. K. Kho, and K. Hadinoto Optimizing aerosolization efficiency of dry-powder aggregates of thermally-sensitive polymeric nanoparticles produced by spray-freeze-drying Powder Technol. 214 2011 169 176
28. K. Kho, W.S. Cheow, R.H. Lie, and K. Hadinoto Aqueous re-dispersibility of spray-dried antibiotic-loaded polycaprolactone nanoparticle aggregates for inhaled anti-biofilm therapy Powder Technol. 203 2010 432 439
29. T.R. Kumar, N.R. Shitut, P.K. Kumar, M.C. Vinu, V.V. Kumar, R. Mullangi, and N.R. Srinivas Determination of rosuvastatin in rat plasma by HPLC: validation and its application to pharmacokinetic studies Biomed. Chromatogr. 20 2006 881 887
30. S. Kumar, R. Gokhale, and D.J. Burgess Sugars as bulking agents to prevent nano-crystal aggregation during spray or freeze-drying Int. J. Pharm. 471 2014 303 311
31. J.M. Lauweryns, and J.H. Baert Alveolar clearance and the role of the pulmonary lymphatics Am. Rev. Respir. Dis. 115 1977 625 683
32. J.K. Liao, and U. Laufs Pleiotropic effects of statins Annu. Rev. Pharmacol. Toxicol. 45 2005 89 118
33. P. Lucas, K. Anderson, and J.N. Staniforth Protein deposition from dry powder inhalers: fine particle multiplets as performance modifiers Pharm. Res. 15 1998 562 569
34. Y.F. Luo, D.W. Chen, L.X. Ren, X.L. Zhao, and J. Qin Solid lipid nanoparticles for enhancing vinpocetine's oral bioavailability J. Control. Release 114 2006 53 59
35. R.H. Müller, M. Radtke, and S.A. Wissing Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations Adv. Drug Deliv. Rev. 54 2002 S131 S155
36. ®) for oral drug delivery Drug Dev. Ind. Pharm. 34 2008 1394 1405
37. M. Manconi, C. Sinico, D. Valenti, G. Loy, and A.M. Fadda Niosomes as carrier for tretinoin. I. Preparation and properties Int. J. Pharm. 234 2002 237 248
38. W. Mehnert, and K. Mäder Solid lipid nanoparticles: production: characterization and applications Adv. Drug Deliv. Rev. 47 2001 165 196
39. A.R. Najafabadi, K. Golani, M. Barghi, and M. Rafiee-Tehrani The effect of vehicle on physical properties and aerosolisation behaviour of disodium cromoglycate microparticles spray dried alone or with L-leucine Int. J. Pharm. 285 2004 97 108
40. A.R. Neves, M. Lucio, S. Martins, J.L. Lima, and S. Reis Novel reseveratrol nanodelivery system based on lipid nanoparticles to enhance its oral bioavailability Int. J. Nanomed. 8 2013 177 187
41. A.S. Nimnual, L.J. Taylor, and D. Bar-Sagi Redox-dependent downregulation of Rho by Rac Nat. Cell Biol. 5 2003 236 241
42. R. Pandey, and G.K. Khuller Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis Tuberculosis 85 2005 227 234
43. A. Patil-Gadhe, and V. Pokharkar Single step spray drying method to develop proliposomes for inhalation: a systematic study based on quality by design approach Pulm. Pharmacol. Ther. 27 2014 197 207
44. R.R. Patlolla, M. Chougule, A.R. Patel, T. Jackson, P.N. Tata, and M. Singh Formulation, characterization and pulmonary deposition of nebulized celecoxib encapsulated nanostructured lipid carriers J. Control. Release 144 2010 233 241
45. D. Pella, R. Rybar, and V. Mechirova Pleiotropic effects of statins Acta Cardiol. Sin. 21 2005 190 198
46. S. Rolin, B. Masereel, and J.M. Dogne Prostanoids as pharmacological targets in COPD and asthma Eur. J. Pharmacol. 533 2006 89 100
47. A. Saez, M. Guzman, J. Molpeceres, and M.R. Aberturas Freeze-drying of polycaprolactone and poly(d,L-lactic-glycolic) nanoparticles induce minor particle size changes affecting the oral pharmacokinetics of loaded drugs Eur. J. Pharm. Biopharm. 50 2000 379 387
48. S. Schurch, P. Gehr, V.I. Hof, M. Geiser, and F. Green Surfactant displaces particles toward the epithelium in airways and alveoli Respir. Physiol. 80 1990 17 32
49. K.A. Shah, A.A. Date, M.D. Joshi, and V.B. Patravale Solid lipid nanoparticles (SLN) of tretinoin: potential in topical delivery Int. J. Pharm. 345 2007 163 171
50. B. Siekmann, and K. Westesen Thermoanalysis of the recrystallization process of melt-homogenized glyceride nanoparticles Colloids Surf. B Biointerfaces 3 1994 159 175
51. C.M. Skold Remodeling in asthma and COPD differences and similarities Clin. Respir. J. 4 2010 20 27
52. Y. Son, and J.T. McConville Development of a standardized dissolution test method for inhaled pharmaceutical formulations Int. J. Pharm. 382 2009 15 22
53. E.A. Stein, D.G. Vidt, J. Shepherd, V.A. Cain, D. Anzalone, and M.D. Cressman Renal safety of intensive cholesterol-lowering treatment with rosuvastatin: a retrospective analysis of renal adverse events among 406,000 participants in the rosuvastatin clinical development program Atherosclerosis 221 2 2012 471 477
54. M.A. Videira, M.F. Botelho, A.C. Santos, L.F. Gouveia, J.J. de Lima, and A.J. Almeida Lymphatic uptake of pulmonary delivered radiolabelled solid lipid nanoparticles J. Drug Target. 10 2002 607 613
55. T. Viganò, A. Hernandez, A. Corsini, A. Granata, P. Belloni, R. Fumagalli, R. Paoletti, and G. Folco Mevalonate pathway and isoprenoids regulate human bronchial myocyte proliferation Eur. J. Pharmacol. 291 1995 201 203
56. K. Vivek, H. Reddy, and R.S. Murthy Investigations of the effect of the lipid matrix on drug entrapment, in vitro release and physical stability of olanzapine-loadedsolid lipid nanoparticles AAPS PharmSciTech 8 2007 E83
57. S.M. Warner, and D.A. Knight Airway modeling and remodeling in the pathogenesis of asthma Curr. Opin. Allergy Clin. Immunol. 8 1 2008 44 48
58. E. Wooltorton Rosuvastatin (Crestor) and rhabdomylosis Can. Med. Assoc. J. 171 2 2004 129
59. W. Yang, J.I. Peters, and R.O. Williams III Inhaled nanoparticles-a current review Int. J. Pharm. 356 2008 239 247
60. X. Zhang, J. Liu, H. Qiao, H. Liu, J. Ni, W. Zhang, and Y. Shi Formulation optimization of dihydroartemisinin nanostructured lipid carrier using response surface methodology Powder Technol. 197 2010 120 128